Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

"Prostate cancer is a worldwide problem. It is the most common cancer in men, with clear racial disparities,” said researcher ...

In Anchorage, Providence Alaska Medical Center has become the first facility in the state to offer an innovative treatment ...

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the Plenary Session on Saturday. Dr. Samir Taneja gave the State-of-the-Art Lecture titled: ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Veracyte (VCYT) announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has ...

Prostate cancer is the second-leading cause of cancer deaths among men in the United States and the rate of men diagnosed with advanced disease has been growing in recent years. 1 Veracyte estimates ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts ...

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...